Helix BioPharma's total assets for Q1 2025 were C$414.00K, a decrease of -72.20% from the previous quarter. TSE:HBP total liabilities were C$1.78M for the fiscal quarter, a 12.60% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.